Serum alpha-feto protein (alpha-FP) and hepatoma in Rhodesian Africans.
Alpha-feto protein (alpha-FP) is now accepted as a very useful serum marker of hepatocarcinoma, and since its discovery in 1963, surveys have been carried out in various regions of the world, where hepatoma is particularly prevalent, which have shown that alpha-FP may be detected in 50 to 80% of patients with liver cancer. The sera of 30 Rhodesian African patients with histologically proven hepatoma were tested in this study for the presence of alpha-FP. In only 47% was alpha-FP detected. Thus it is our experience that a positive result is strong evidence in favour of a diagnosis of hepatocarcinoma whilst a negative result is of little value, necessitating that liver biopsy be carried out in all patients with clinical suspicion of liver cancer.
D000293:Adolescent; D000328:Adult; D000368:Aged; D044383:Black People; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000175:diagnosis; D005260:Female; D005326:Fetal Proteins / Q000032:analysis*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D015030:Zimbabwe; D000509:alpha-Fetoproteins / Q000032:analysis*
D005326:Fetal Proteins; D000509:alpha-Fetoproteins